Kornimate/medical-research-clean huggingface dataset:
massage therapy and the well-being of police officers

Conditions: Occupational Problems; Occupational Injuries; Occupation-related Stress Disorder

Summary: this study is intend to show the positive impact that massage therapy can have on the lives of police officers. the study will demonstrate how regular treatment can change sleeping quality, stress levels and mental health. it will also investigate the impact that police work can have on the body.


Eligibility criteria:
inclusion criteria: * police officers preferable working on the street within the st. john's area exclusion criteria: * civilians

Keywords: police officers
sentinel node mapping in women with endometrial and cervical cancer

Conditions: Uterine Cervical Neoplasms; Uterine Neoplasms

Summary: the aim of the study is to evaluate the feasibility of applying the sln mapping technique in combination with fdg-pet/ct imaging in women with high-risk histology endometrial cancer and in patients with cervical cancer tumour size 2-4 cm.


Eligibility criteria:
inclusion criteria: * study iia: patients with cervical cancer, figo ib1, tumor size 2-4 cm * study iib: patients with high risk endometrial cancer, presumed figo i, type 1 histology grade 3 endometrioid adenocarcinoma or type 2 histology (serous-, clearcel-, carcinosarcoma or undifferentiated adenocarcinoma. exclusion criteria: * prior pl * known allergy towards icg and/or iodine (icg contains 5% sodium iodine) * women included in other studies affecting outcome-measures of the present study

Keywords: robotic surgery procedures indocyanine green sentinel lymph node mapping
accurate staging of immuno-virological dynamics during acute hiv infection

Conditions: HIV; Seroconversion, HIV

Summary: in this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (hiv) viral reservoir, established during early hiv infection and responsible for viral rebound at treatment interruption, evolve in individuals who start combination anti-retroviral therapy (cart) during acute seroconversion. recently infected patients will be selected based on fiebig staging for an in depth sampling protocol at different timepoints during a 2 year follow up period. colonbiopsies, lymphnode resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be performed. immunological, virological and genome expression analysis will be performed on the gathered samples.


Eligibility criteria:
inclusion criteria: * documented recent hiv-1 infection, early diagnosis: clinical symptoms of acute seroconversion and incomplete western blot or negative screening test within the past 6 months and incomplete western blot or risk contact within the 3 months and presumable primo-infection with or without clinical symptoms and incomplete western blot * able and willing to provide written informed consent * ability to attend the complete schedule of assessments and patient visits for patients participating in option a schedule (described below), or ability to attend a partial schedule of assessments and patient visits for patients participating in option b (described below). * ability and willingness to have blood and tissue samples collected and stored indefinitely and used for various research purposes. exclusion criteria: * previous or current history of opportunistic infection (aids defining events as defined in category c of the cdc clinical classification), consisting of chronic hiv-1 infection. * evidence of active hbv infection (hepatitis b surface antigen positive or hbv viral load positive in the past and no evidence of subsequent seroconversion (=hbv antigen or viral load negative and positive hbv surface antibody). * evidence of active hcv infection: hcv antibody positive result within 60 days prior to study entry with positive hcv viral load or, if the hcv antibody result is negative, a positive hcv rna result within 60 days prior to study entry. * current or known history of cardiomyopathy or significant ischemic or cerebrovascular disease. * current history of cancer. * pregnancy or breastfeeding. * any conditions, including psychiatric and psychological disorders, which will in the opinion of the investigator interfere with the trial conduct or safety of the participant. * previous participation in a trial evaluating an immune modulating agent * abnormal laboratory tests results at screening: confirmed hemoglobin \ 3xuln * active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. * acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and/or hospitalization within 60 days prior to entry.

Keywords: reservoir
a digital non-interventional atrial fibrillation (af) screening study with commercial pulse detection systems

Conditions: Atrial Fibrillation

Summary: the primary objective in this study is to identify commercial pulse detection systems (cpds) parallel to electrocardiogram (ecg) recording within routine clinical setting, which are able to detect atrial fibrillation or sinus rhythm of screened patients.


Eligibility criteria:
inclusion criteria: * adult female and male patients for whom the decision to record an ecg was made as per investigator's routine treatment practice * patient able and willing to provide signed informed consent exclusion criteria: * patients with any comorbidities or abnormalities of heart function or rhythm, which might, in the opinion of the investigator, interfere with the evaluation of study data * patients participating in an investigational program with interventions outside of routine clinical practice

Keywords: sinus rhythm
comparative effectiveness study of bubble cpap devices in the nicu

Conditions: Respiratory Distress Syndrome

Summary: multiple different devices are available to provide bubble cpap to preterm and newborn infants. the most significant difference between these devices is the size of the bubble produced by the exhalation limb. this study will determine if one bubble cpap device (babiplus vs b\&b) is more effective in improving oxygenation and decreasing extubation failure in the extremely low birthweight population.

primary outcome: bubble cpap failure (re-intubation or use of non-invasive positive pressure ventilation) within 72 hours following extubation secondary outcome: number of infants that reach 21% inspired oxygen during initial study period secondary outcome: apnea/bradycardia events in the initial study period secondary outcome: mean oxygen requirement following initial study period population: infants born at \ = 500 grams birth weight randomization: equal allocation stratified by gestational age (\ =27 weeks) study diagram: 72h 24h x----------\>x1-----------\>y2 y----------\>y1-----------\>x2 infants will be randomly assigned to treatment x (babiplus, control group) or treatment y (b\&b bubbler, intervention group). the primary outcome is bubble cpap failure during the first 72 hours following extubation, measured at time point 1 in the diagram. bubble cpap failure is defined as requiring re-intubation or non-invasive positive pressure ventilation (nippv), requiring fio2 of \>60% for one hour or a pco2 measurement of \>65 mm hg. for those infants that remain on cpap during the initial study period, the number that reach 21% inspired oxygen for \>12 consecutive hours will be compared between groups. this difference will also be analyzed using a chi square test. those infants that remain on cpap following the 72 hour initial study period (e.g., did not meet primary outcome criteria) will be crossed over to the opposite treatment arm for at least 24 hours. the minimum oxygen requirement required to keep the saturations in the ordered range, per standard nicu guidelines, will be recorded and compared between time points 1 and 2. this study design is complex due to the nature of the disease of these patients. each day every infant's premature pulmonary disease is evolving. there is no way to control for this.

Eligibility criteria:
inclusion criteria: 1. infant delivered at \>=500 grams and \<=1250 grams birth weight. 2. infant requires intubation for mechanical ventilation within the first 48 hours following delivery. 3. infant has received exogenous surfactant during mechanical ventilation. exclusion criteria: 1. decision by attending physician to redirect to comfort care 2. congenital condition that precludes the use of cpap (choanal atresia, diaphragmatic hernia, etc.) 3. birth weight \>1250 grams or \<500 grams. 4. non-english speaking parents. -

Keywords: continuous positive airway pressure cpap bubble cpap extubation failure preterm infant
c9,t11-cla in children and adolescents with allergic asthma

Conditions: Allergic Bronchial Asthma

Summary: the study was performed to investigate the effects of a dietary intervention with c9,t11-cla on clinical and immunological parameters in children and adolescents with allergic bronchial asthma.

in-vitro and animal studies strongly suggest that c9,t11-cla reduces inflammatory processes in asthma-models. aim of this study was to determine possible beneficial effects of orally administered c9,t11-cla in children and adolescents with allergic bronchial asthma. thirty subjects (14 girls, 16 boys, age 6-18 years) were recruited from regular patients in the clinic for pediatric allergology of the friedrich schiller university jena. informed consent was obtained from all participants/parents. 29 subjects completed the study. the study was designed as a randomized and placebo-controlled study. after a 1-week run-in period to ascertain the current state of disease and categorization of allergic sensitization by rast, the participants were randomized and evenly distributed to receive either 3 g/d of an esterified cla preparation free of t10,c12-cla (75% c9,t11-cla, 87% purity) or 3 g/d of a placebo oil mixed in 100 g portions of milk fat-free yoghurt for 12 weeks. the yoghurt was freshly prepared and distributed in frequent intervals. at the beginning and at the end of the study, lung function parameters were assessed by whole body plethysmography, and venous blood and 24h-urine samples were collected for further analyses. throughout the entire study, the participants daily recorded their peak-flow data and kept protocol about their symptoms and drug usage.

Eligibility criteria:
inclusion criteria: * age 6-18 years * doctor-diagnosed bronchial asthma * allergic sensitization (house dust mite, grass pollen) * willingness to use only the recommended drugs * competence regarding the daily documentation of peak-flow data and symptoms exclusion criteria: * sit within the last 2 years * primary and secondary immune deficiency * usage of systemic corticoids * intolerance against milk protein * alcohol and drug abuse

Keywords: c9,t11-cla allergic bronchial asthma children and adolescents
artificial intelligence/computer guided ridge splitting for treating horizontal ridge defects

Conditions: Alveolar Bone Resorption; Dental Implant Failure Nos

Summary: aim of the current randomized clinical trial is to evaluate and compare the effectiveness of computer-guided ridge splitting approach assisted by artificial intelligence versus conventional approach combined with simultaneous implant placement.

ridge split technique is considered one of the successful horizontal bone augmentation procedures especially in maxilla for the management of horizontal ridge defects. this was adapted by summers in 1994. guided implant surgery was used in dental implant surgery to achieve accuracy and an overall predictability. successful guided implant workflow depends on 3-dimensional image acquisition and precise model fabrication. artificial intelligence application in implant dentistry has ushered in a new era of precision and efficiency demonstrating improved implant survival rates and patient satisfaction and enhance the integration of technologies with digital workflows.

Eligibility criteria:
inclusion criteria: * the target population with inadequate bone volume for implant placement due to width insufficiency of maxillary anterior alveolar ridges. * age ranges from 25-40 years of both sexes. * no gender restrictions were considered for initial screening. * absence of any complicating systemic condition that may contraindicate surgical procedures and implant placement. * adequate oral hygiene. * eligible participants should present good general health and agree to random assignment to any of the two parallel study groups. * participants had minimum 3 months as post extraction healing period and horizontal maxillary anterior ridge defects with at least bone width of 3 mm and bone height of 13 mm. exclusion criteria: * vertical ridge defect. * undercut on the labial/buccal side. * thick cortical bone without cancellous bone inside. * uncontrolled systematic disorders as, diabetes mellitus, uncontrolled periodontal disease, history of head and neck radiotherapy, smokers, pregnancy, noncompliant patients, allergy to the used medications, uncooperative individuals or those unable to attend the study follow-up appointments.

Keywords: artificial intelligence ridge splitting computer-guided surgery
keratometric tear breakup time and fluorescein tear breakup time

Conditions: Dry Eye

Summary: the purpose of the research is to determine if putting fluorescein onto the eye (most common test done for dry eye syndrome) is an accurate way to measure dry eye symptoms. the investigators can avoid placing any foreign substance into the eye by using a manual keratometer. therefore, the investigators want to compare the measurements of tear breakup time using fluorescein with using a novel method, a manual keratometer and then compare these measurements to a validated dry eye symptoms questionnaire. all qualifying patients who were scheduled in the jones eye institute clinics for a complete eye exam were offered information about the study and invited to participate. participants were recruited from february 29, 2009 to april 14, 2009.participants who did not meet the study protocol's inclusion and exclusion criteria were not included the study or study data analysis. all subjects eyes were measured for ktbut and ftbut.

this is an observational study to measure the difference between keratometric tear break up time (ktbut) and fluorescein tear break up time (ftbut). all qualified study participants had their eyes measured for tear break up time measured with a keratometer and with fluorescein dye. in this study, we compare the use of the most common method, fluorescein dye, to measure tear break up time to a novel method, a keratometer, to measure tear break up time. using the keratometer avoids instilling fluorescein dye into the tear film and not altering the tear film's physiologic environment.

Eligibility criteria:
inclusion criteria: * an adult, between ages 18-99 * an adult who is able to understand study instructions exclusion criteria: * an adult with corneal pathology that prevents accurate assessment of keratometric or fluorescein tear break up time. * an adult with an allergy to fluorescein, a very common eye dye that detects defects in the cornea. * the inability to answer questions on your own.

Keywords: dry eye keratometer fluorescein
the acute effect of proprioceptive neuromuscular facilitation on cervical range of motion, strength and proprioception.

Conditions: Proprioception; Neck

Summary: the aim of the study was to investigate the immediate influence of proprioceptive neuromuscular facilitation on cervical range of motion, strength and proprioception

the study evaluates the influence of two proprioceptive neuromuscular facilitation techniques (pnf patterns and pnf stretching) on cervical proprioception. pnf techniques are regularly used techniques among physiotherapist. also there is a lack of studies that investigated the effect of pnf on cervical proprioception

Eligibility criteria:
inclusion criteria: * neck disability index score of 5 or less * able to understand and follow instructions * above 18 years old exclusion criteria: * cervical trauma * history of cervical inter-vertebral disc pathology * rheumatic diseases * whiplash syndrome * history of surgeries to the neck, face and shoulders * history of systemic diseases

Keywords: proprioception proprioceptive neuromuscular facilitation, cervical spine stretching
birmingham hip resurfacing (bhr) study: implantation of a hip resurfacing endoprosthesis

Conditions: Arthritis

Summary: the purpose of this study is the investigation of the functional and radiological results and subjective patient outcome after the implantation of a hip resurfacing endoprosthesis (birmingham hip resurfacing).

high volumetric wear of polyethylene was the main factor in periprosthetic bone resorption and failure of historic hip resurfacing prosthesis. metal-on-metal devices reduce the wear substantially and may solve this problem. the purpose of this study is the investigation of the functional and radiological result and subjective patient outcome after implantation of a hip resurfacing endoprosthesis (birmingham hip resurfacing) during the first two years after surgery.

Eligibility criteria:
inclusion criteria: * clinical and radiological signs of coxarthritis * implantation of a total hip replacement indicated * informed consent exclusion criteria: * osteoporosis * tumor * acute infection * higher grade congenital dysplasia of the hip * pregnancy

Keywords: arthritis hip hip arthroplasty hip resurfacing arthroplasty
laparoscopic surgery or standard surgery in treating patients with endometrial cancer or cancer of the uterus

Conditions: Endometrial Adenocarcinoma; Stage I Uterine Corpus Cancer; Stage I Uterine Sarcoma; Stage II Uterine Corpus Cancer; Stage II Uterine Sarcoma

Summary: this randomized phase iii trial is studying laparoscopic surgery to see how well it works compared to standard surgery in treating patients with endometrial cancer or cancer of the uterus. laparoscopic surgery is a less invasive type of surgery for cancer of the uterus and may have fewer side effects and improve recovery. it is not known whether laparoscopic surgery is more effective than standard surgery in treating endometrial cancer.

objectives: i. compare the incidence of surgical complications, peri-operative morbidity, and mortality in patients with stage i or iia, grade i-iii endometrial cancer or uterine cancer undergoing surgical staging through laparoscopic assisted vaginal hysterectomy vs total abdominal hysterectomy. ii. compare the length of hospital stay after surgery in patients receiving these treatments. iii. compare the quality of life of patients receiving these treatments. iv. compare the incidence and location of disease recurrence in patients receiving these treatments. outline: this is a randomized, multicenter study. patients are randomized to 1 of 2 treatment arms. arm i: patients undergo vaginal hysterectomy and bilateral salpingo-oophorectomy (bso) via laparoscopy. arm ii: patients undergo total abdominal hysterectomy and bso via conventional laparotomy. patients in both arms also undergo pelvic and para-aortic lymph node sampling. quality of life is assessed at baseline, at 1, 3, and 6 weeks, and then at 6 months. patients are followed at 6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

Eligibility criteria:
inclusion criteria: * diagnosis of stage i or iia, grade i-iii endometrial adenocarcinoma or uterine sarcoma * must be considered a candidate for surgery * no contraindication to laparoscopy * no clinical or chest x-ray evidence of metastasis beyond the uterine corpus or macroscopic involvement of the endocervix * performance status - gog 0-3 * wbc at least 3,000/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin no greater than 1.5 times normal * sgot no greater than 3 times normal * creatinine no greater than 2.0 mg/dl * prior malignancy allowed if no current evidence of disease * not pregnant * no prior pelvic or abdominal radiotherapy * see disease characteristics * no prior retroperitoneal surgery
long term impact of rapid intravenous infusion of velaglucerase alfa (vpriv)

Conditions: Gaucher Disease, Type 1

Summary: background: in order to allow our satisfied patients, who have successfully completed 24 months of rapid intravenous infusion of velaglucerase alfa (vpriv), to continue with the 10 minutes iv therapy, the clinical trial framework must be extended; and this extension is important for the assessment of long term benefit (up to 5 years) of this regimen of administration of velaglucerase alfa.. suggested trial: an additional 36 months home therapy follow up of safety and efficacy of rapid intravenous infusion of velaglucerase alfa (vpriv) in adult patients with type 1 gaucher disease. patients must have completed the prior 4 parts / 24 months of the protocol before enrolling into this extension phase ("part 5") and have provided a new consent before entering part 5 of the study. patients must not have experienced clinically significant aes, including allergic reactions, in any of the prior study parts of this protocol to be eligible to participate, and have maintained stability in the key disease features. all infusions of 10' will be given in the context of home therapy. "clinically significant" aes will be determined by the pi using standard description of aes as previously described at phase 3, and if necessary will support withdrawal of the patient from the study.

every 6 months, patients will be required to come for routine checkups at szmc, where the following tests will be performed: * complete blood count (cbc) * routine serum biochemistry including liver function tests (lfts) * plasma biomarker lyso gb-1 * height \& weight \& calculation of bmi * physical examination and medical history elicited including concomitant medications * ultrasound for spleen and liver volumes in addition, the following tests will be performed at 12, 24 and 36 months: * echocardiography * electrocardiogram (ecg) * urinalysis * hrqol questionnaire (tbd) at each home visit, the following assessments will be performed by the study nurse: queries regarding aes and changes in clinically relevant gaucher parameters as described by the patient (e.g., bone pain), inter-current illnesses, etc. patients will be required to complete the end-of-study visit, including the final infusion at 10', at szmc. this final visit will include in addition to the usual safety and efficacy assessments and routine tests, (mentioned above) also, dexa and anti-drug antibodies. in addition, we would perform a 4th pk measurement at end of the extension period.

Eligibility criteria:
inclusion criteria: * aged 18-75 years, non-splenectomized enzymatic diagnosis \& molecular analysis indicative of type 1 gaucher disease receiving vpriv for at least 6 infusions (3 months) prior to baseline at a constant dose and frequency and without clinically significant aes including allergic reactions exclusion criteria: * experience of a clinically significant ae to vpriv at any time in the past existence of a clinically significant co-morbidity
repeat ablation procedure in patients with relapse of atrial fibrillation

Conditions: Ablation; Paroxysmal Atrial Fibrillation

Summary: catheter ablation with isolation of the pulmonary veins has proven to be an effective treatment option in patients with paroxysmal atrial fibrillation. in patients who have a relapse of paroxysmal atrial fibrillation after one ablation procedure the investigators compare the reisolation of all pulmonary veins to reisolation plus an anterior left atrial line.

catheter ablation with isolation of the pulmonary veins has proven to be an effective treatment option in patients with paroxysmal atrial fibrillation. in patients who have a relapse of paroxysmal atrial fibrillation after one ablation procedure we compare the reisolation of all pulmonary veins to reisolation plus an anterior left atrial line.

Eligibility criteria:
inclusion criteria: * relapse of atrial fibrillation exclusion criteria: * contraindication for ablation